Academic Training in Therapeutic Advancement for Child Health (ATTACH)

虽然近年来在成人药物治疗方面取得了巨大进展，但扩大了药物治疗的范围。 这些新疗法对婴儿和儿童的益处仍然是一个重大挑战。重要的发展 药代动力学、药效学、疾病表现和进展的变化都阻碍了直接的 将成人治疗学转化为儿科学。儿科临床药理学学科提供 发育生理学的必要培训，以利用现有知识并指导合理的治疗 为婴儿和儿童。然而，目前的药理学家和儿科专家与正式的 临床药理学培训既少又老。接受过以下培训的其他儿科临床医生-科学家 迫切需要临床药理学来确保针对婴儿和儿童的最佳治疗。在 2015年，在Edmund Capparelli，PharmD（儿科药代动力学（PK）建模专家）的领导下 和Adriana Tremoulet，医学博士，MAS（儿科临床试验专家），在儿科临床药理学培训， UC San Diego正式成为NICHD支持的T32培训计划。我们为第一次迭代感到自豪 提供儿科临床药理学前沿研究培训的正式项目。我们现建议 更新我们的T32儿科临床药理学培训计划，题为“学术培训，在治疗 促进儿童健康”（附件）。在这次更新中，我们自豪地寻求（1）使我们的计划现代化， 新的项目领导，（2）招募更多世界知名的教师，教我们的研究员国家的最先进的 技术，（3）推出一个系统的工具，以评估我们的计划的表现，并协助计划 改进，（4）强调学员和教师导师培训，以及（5）改进招聘方法，以吸引 申请人和受训人员更加多样化，以促进劳动力的多样化。我们的主要目标 我们的培训计划的第一个周期将保持不变：（1）增加儿科临床 药理学家和临床科学家从事临床药理学研究，适用于儿童健康; (2)吸引优秀的年轻儿科临床医生到UCSD，并通过以下方式扩大他们的翻译能力： 临床药理学方法;（3）在以下指导下促进ATTACH学员的职业发展： 世界级的，建立了教师导师;（4）培养妇女和少数民族的早期职业生涯 儿科治疗学的研究者。与我们令人印象深刻的导师团队一起， 记录，UCSD ATTACH研究员将准备成为明天的领导者在儿科临床药理学。

While tremendous advances in pharmacotherapy for adults have been achieved in recent years, expanding the benefits of these new therapies to infants and children remains a significant challenge. Important developmental changes in pharmacokinetics, pharmacodynamics, disease presentation and progression all impede direct translation of adult therapeutics into pediatrics. The discipline of pediatric clinical pharmacology provides necessary training in developmental physiology to leverage existing knowledge and guide rational therapeutics for infants and children. However, the current pool of pharmacologists and pediatric sub-specialists with formal training in clinical pharmacology is both small and aging. Additional pediatric clinician-scientists with training in clinical pharmacology are urgently needed to ensure that therapies are optimized for infants and children. In 2015, under the leadership of Edmund Capparelli, PharmD (expert in pediatric pharmacokinetic (PK) modeling) and Adriana Tremoulet, MD, MAS (expert in pediatric clinical trials), training in pediatric clinical pharmacology at UC San Diego was formalized as a NICHD-supported T32 Training Program. We are proud of this first iteration of a formal program to provide cutting-edge research training in pediatric clinical pharmacology. We now propose a renewal of our T32 pediatric clinical pharmacology training program, entitled “Academic Training in Therapeutic Advancement for Child Health” (ATTACH). In this renewal, we proudly seek to (1) modernize our program with new program leadership, (2) recruit more world-renowned faculty to teach our fellows state-of-the-art technologies, (3) launch a systematic tool to assess performance of our program and assist in program improvement, (4) emphasize trainee and faculty mentor training, and (5) enhance recruitment methods to attract a more diverse pool of applicants and trainees to stimulate diversity in the workforce. Our key objectives of the first cycle of our training program will remain the same: (1) To increase the number Pediatric clinical pharmacologists and Clinician-Scientists engaged in clinical pharmacology research as applied to child health; (2) to attract outstanding young pediatric clinicians to UCSD and to expand their translational capacity through clinical pharmacology methods; (3) to facilitate career development of ATTACH trainees under the guidance of world class, established investigator-faculty mentors; and (4) to cultivate the early careers of women and minority investigators in pediatric therapeutics. With our impressive group of mentors with outstanding training track records, UCSD ATTACH Fellows will be poised to be tomorrow's leaders in pediatric clinical pharmacology.